Keytruda And FDA’s Oncology Center of Excellence: The Regulatory Milestones Keep Coming

Merck’s anti-PD-1 therapy Keytruda keeps piling up new indications, including three approved by US FDA in just two weeks – all during a pandemic. The remarkable therapy has been a centerpiece for an equally remarkable period of regulatory innovation.

Asphalt road with arrow guideline and Milestone letters painted on the surface. An image of a road milestones are representative of success in the future goal. Road to success with light of the sun

The US Food & Drug Administration’s 29 June approval of another new indication for Merck’s blockbuster anti-PD-1 cancer treatment Keytruda (permbrolizumab) is all too easy to overlook.

Amid the COVID-19 pandemic, the extension of the Keytruda label to yet another cancer type – in this case, patients...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards